GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (FRA:8BT0) » Definitions » Notes Receivable

BriaCell Therapeutics (FRA:8BT0) Notes Receivable : €0.00 Mil (As of Jan. 2025)


View and export this data going back to 2015. Start your Free Trial

What is BriaCell Therapeutics Notes Receivable?

BriaCell Therapeutics's Notes Receivable for the quarter that ended in Jan. 2025 was €0.00 Mil.


BriaCell Therapeutics Notes Receivable Historical Data

The historical data trend for BriaCell Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Notes Receivable Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BriaCell Therapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BriaCell Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


BriaCell Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics Business Description

Traded in Other Exchanges
Address
235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

BriaCell Therapeutics Headlines

No Headlines